by Maria Zannes | Sep 28, 2022 | Press Releases
SAN ANTONIO, TX – September 28, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the...
by Maria Zannes | Sep 6, 2022 | Press Releases
San Antonio, TX – September 6, 2022 – bioAffinity Technologies, Inc. (“bioAffinity” or the “Company”) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching...
by Maria Zannes | Sep 1, 2022 | Press Releases
SEPTEMBER 1, 2022(SAN ANTONIO, TX) bioAffinity Technologies, Inc., a cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that...
by Maria Zannes | Mar 24, 2022 | Events
Maria Zannes, President & CEO, will discuss keys to a start-up company’s success as part of San Antonio BioMed’s BioFest Invest event on March 30, 2022. Zannes will be on a panel of CEOs presenting to investors, companies and business leaders at the annual spring...
by Maria Zannes | Dec 6, 2021 | Events
bioAffinity discoveries lead to novel approach that kills cancer cells without harm to normal cells by using siRNAs to selectively target multiple cancers DECEMBER 6, 2021 (SAN ANTONIO, TX) bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how...
